Study on Stereotactic Ablative Radiotherapy (SABR) for Treating Patients with Metastatic Cancer, ID-COMET Trial

Inclusion Criteria

• Age 1 year or older.
• Willing to provide informed consent.
• ECOG performance status of 3 or less, meaning you can still perform some daily activities.
• Life expectancy of more than 6 months.
• For Trials 1-3: Diagnosed with lung, prostate, or colorectal cancer that has spread to other parts of the body, confirmed by imaging. A biopsy of the spread is preferred but not required.
• For Trial 4: Any type of cancer with spread. Patients with blood cancers are eligible if they have confirmed disease that is resistant to treatment and are eligible for radiation therapy.
• Newly diagnosed metastatic patients for Trials 1-3. Previously diagnosed metastatic patients for Trial 4.
• Recent imaging tests completed within 12 weeks before joining the study.
• For those receiving chest radiation, a doctor must confirm there are no signs of lung disease on previous CT scans. If there are signs, a lung specialist must rule out lung disease before joining.
• Participants who can have children must agree to use effective birth control methods before joining the study.
• If a woman becomes pregnant or thinks she might be while participating, she should inform her doctor immediately.
• Must understand the study is experimental and sign a consent form before any study procedures.

Exclusion Criteria

• No option for standard treatment or refusal of standard treatment.
• Recent chemotherapy or radiation within 3 weeks (or 6 weeks for certain drugs) before joining the study, or not recovered from side effects of previous treatments.
• Serious health conditions that prevent radiation therapy, such as lung disease for chest radiation, Crohn's disease for gastrointestinal radiation, or connective tissue disorders like lupus.
• Moderate to severe liver problems for those with liver cancer spread.
• Overlapping previous radiation treatment areas that exceed safe limits.
• Malignant fluid buildup in the chest.
• Inability to treat all cancer sites.
• Cancer that has spread to the digestive tract or skin.
• Known brain cancer spread due to poor prognosis and potential for worsening symptoms.
• Uncontrolled health issues like infections, heart failure, unstable chest pain, irregular heartbeats, or mental health conditions that affect study participation.
• Pregnant or breastfeeding women.